Journal article · 2023 · Open access
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
The Lancet, 402(10408), 1133–1146 · Published 24 July 2023 · DOI 10.1016/s0140-6736(23)00961-3
In brief
“Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study” is a 2023 journal article by Shukui Qin and 135 co-authors, published in The Lancet. OpenAlex counts 860 citations as of 21 November 2026. It is open access under a CC BY-NC-SA licence: the full text is free to read at Florence Research (University of Florence).
- Citations
- 860
- Most cited in
- 2025 (308)
- Field-weighted impact
- 94.95
- References
- 45
- Authors
- 136
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jin, Y., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., . . . Verset, G. (2023). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet, 402(10408), 1133–1146. https://doi.org/10.1016/s0140-6736(23)00961-3
MLA 9
Qin, Shukui, et al. “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.” The Lancet, vol. 402, no. 10408, 2023, pp. 1133–1146. https://doi.org/10.1016/s0140-6736(23)00961-3.
Chicago
Qin, Shukui, Stephen L Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, et al. 2023. “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.” The Lancet 402 (10408): 1133–1146. https://doi.org/10.1016/s0140-6736(23)00961-3.
Harvard
Qin, S. et al. (2023) ‘Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study’, The Lancet, 402(10408), pp. 1133–1146. doi:10.1016/s0140-6736(23)00961-3.
IEEE
S. Qin et al., “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study,” The Lancet, vol. 402, no. 10408, pp. 1133–1146, 2023, doi: 10.1016/s0140-6736(23)00961-3.
BibTeX
@article{qin2023camrelizumab,
title = {{Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study}},
author = {Qin, Shukui and Chan, Stephen L and Gu, Shanzhi and Bai, Yuxian and Ren, Zhenggang and Lin, Xiaoyan and Chen, Zhendong and Jin, Yongdong and Jin, Yongdong and Guo, Yabing and Hu, Xiaohua and Meng, Zhiqiang and Liang, Jun and Cheng, Ying and Xiong, Jianping and Ren, Hong and Yang, Fang and Li, Wei and Chen, Yajin and Zeng, Yong and Sultanbaev, Alexander and Pazgan-Simon, Monika and Pisetska, Margaryta and Melisi, Davide and Ponomarenko, Dmitriy and Osypchuk, Yurii and Sinielnikov, Ivan and Yang, Tsai-Sheng and Liang, Xiao and Chen, Chunxia and others},
journal = {The Lancet},
year = {2023},
volume = {402},
number = {10408},
pages = {1133--1146},
doi = {10.1016/s0140-6736(23)00961-3},
url = {https://doi.org/10.1016/s0140-6736(23)00961-3}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 32 | |
| 2024 | 256 | |
| 2025 | 308 | |
| 2026 | 262 |
Its field-weighted citation impact is 94.95: it has been cited 94.95 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- camrelizumab
- apatinib
- sorafenib
- hepatocellular carcinoma
- unresectable liver cancer
- first-line therapy
- immune checkpoint inhibitors
- anti-PD-1 therapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jin, Y., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., . . . Verset, G. (2023). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet, 402(10408), 1133–1146. https://doi.org/10.1016/s0140-6736(23)00961-3
How many times has this paper been cited?
860 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Florence Research (University of Florence): sign in and open the full text from this page.
Who wrote this paper?
Shukui Qin, Stephen L Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Yongdong Jin, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng and 124 more.
What is the DOI of this paper?
10.1016/s0140-6736(23)00961-3, permanently at https://doi.org/10.1016/s0140-6736(23)00961-3. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.